<DOC>
	<DOCNO>NCT02504151</DOCNO>
	<brief_summary>Cannabidiol ( CBD ) component herbal cannabis present vary concentration cannabis extract . CBD show produce central effect include hypnotic , anticonvulsive , anxiolytic neuroprotective effects.The investigator hypothesize treatment CBD result : 1 ) Improvement evidence reduction score Positive Negative Syndrome Scale Schizophrenia ( PANSS ) , 2 ) Improvement evidence reduction Clinical Global Impression Severity scale ( CGI ) ; Secondary Hypothesis : 1 ) Greater improvement functioning measure `` Patient Assessment Own Functioning Inventory : ( PAOFI ) Quality Life Scale ( QLS ) In 2 period cross design , subject randomized 1:1 ratio receive either : Order 1 : CBD ( Period 1 ) follow placebo ( Period 2 ) Order 2 : Placebo ( Period 1 ) follow CBD ( Period 2 ) double-blind condition . The 2 study period separate washout least 2 week . During period subject receive study medication ( CBD [ total 800mg/day ] placebo ) period 4 week .</brief_summary>
	<brief_title>Cannabidiol Treatment Patients With Early Psychosis</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Male female Primary psychotic disorder Ages 1865 ( inclusive ) Current significant medical condition comorbidities Current substance depdendence Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>